Asia Pacific Precision Diagnostics Market

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2028

Analysis – by Type (Genetic Tests, Esoteric Tests, and Others), Application (Oncology, Cardiology, Respiratory Diseases, Immunology, and Others), and End User (Clinical Laboratories, Hospitals, Homecare, and Others) 


No. of Pages: 142    |    Report Code: BMIRE00026143    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Buy Now
Asia Pacific Precision Diagnostics Market

The precision diagnostics market in Asia Pacific is expected to grow from US$ 15,157.61 million in 2022 to US$ 33,007.52 million by 2028. It is estimated to grow at a CAGR of 13.8% from 2022 to 2028.

 

The advancement in artificial intelligence (AI) is increasing. Healthcare is expected to lead the way in AI investments between 2018 and 2022, with the Asia Pacific region well-positioned to grow due to its fertile digital ecosystem, as per Industry analysts. According to the recently released Philips Future Health Index, healthcare professionals in Singapore are leaders in using AI, with 55% using AI in their daily practice compared to an average of 46% across the 15 countries surveyed. Diagnosis of complex diseases such as cancer can be time-consuming and labor-intensive because many factors are to be considered, such as disease type, physical exams, genomic and molecular data analysis, and the patient’s medical history. Intelligently aggregating all this information is the hallmark of precision diagnosis.

 

As per a study by International Data Corporation (IDC), the amount of data in healthcare is growing by an estimated 48% every year, leaving less time for physicians to study it. In addition, the rising disease burden in the aging population would increase the data mount. In a country, such as Singapore, up to eight in ten doctors report feeling burnt out as they struggle to keep up with the rising workload. By automating the mundane and speeding up workflows, AI can help alleviate overburdened physicians.

 

The ability of AI to shift through large amounts of data has the potential to make medical examinations more precise, reliable, and efficient. For instance, in CT-based lung cancer screening, Philips researchers have demonstrated that a deep learning algorithm can be helpful to radiologists as a decision support tool.

Similarly, in digital pathology, algorithms can help point to regions of interest in tissue samples that demand further inspection by the pathologist. Targeted treatments that enable an individual to get better can be understood by unraveling the molecular mechanisms that give rise to an individual’s disease.

 

Moreover, in healthcare, machine learning (ML) can be beneficial in many areas, including biomedical data management, automation of diagnoses, and biomarker discovery. Biomarker discovery can be used to build better biomarkers to predict a patient’s response to therapy. The big data from a biological system, such as the human body, needs to be understood to do so.

 

The current method of applying MI to biomarker discovery is making feature selections across multiple levels of omics data that predict outcomes between different cohorts. The power of MI and Ribonucleic acid (RNA) to build Health Expression Models can also help capture complex biology and enable quantification in heterogeneous tissue samples. Thus, using MI to make precision diagnostics will change the future of precision medicine, allowing the right patient to receive proper treatment at the right time.

 

Machine learning and artificial intelligence techniques are starting to provide doctors with new diagnostic insights. A French start-up, VitaDx, uses fluorescent imaging and MI to improve the early diagnosis of bladder cancer by analyzing the shape, physiology, and metabolism of potentially cancerous cells. The technology can also be applied later for the early diagnosis of cancers of the lungs, stomach, and thyroid. Therefore, the advantages offered by AI and MI are expected to create numerous future trends for the precision diagnostics market.

 

 Asia Pacific Precision Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

https://www.businessmarketinsights.com/assets/rdimages//asia-pacific-precision-diagnostics-market-img1.PNG
Get more information on this report

Asia Pacific Precision Diagnostics Strategic Insights

Strategic insights for the Asia Pacific Precision Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-precision-diagnostics-market-strategic-framework.webp
Get more information on this report

Asia Pacific Precision Diagnostics Report Scope

Report Attribute Details
Market size in 2022 US$ 15,157.61 Million
Market Size by 2028 US$ 33,007.52 Million
Global CAGR (2022 - 2028) 13.8%
Historical Data 2020-2021
Forecast period 2023-2028
Segments Covered By Type
  • Genetic Tests
  • Esoteric Tests
By Application
  • Oncology
  • Cardiology
  • Respiratory Diseases
  • Immunology
By End User
  • Clinical Laboratories
  • Hospitals
  • Homecare
Regions and Countries Covered Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
Market leaders and key company profiles
  • Abbott
  • Bayer AG
  • Koninklijke Philips N.V.
  • Novartis AG
  • QIAGEN
  • Quest Diagnostics Incorporated
  • Sanofi
  • Siemens Healthineers AG
  • Swiss Precision Diagnostics GmbH
  • Get more information on this report

    Asia Pacific Precision Diagnostics Regional Insights

    The geographic scope of the Asia Pacific Precision Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

    geography/asia-pacific-precision-diagnostics-market-geography.webp
    Get more information on this report

     

     

    Asia Pacific Precision Diagnostics Market Segmentation        

     

    The Asia Pacific precision diagnostics market is segmented by type, application, end user, and country. Based on type, the market is segmented into genetic tests, esoteric tests, and others. The genetic tests segment dominated the market in 2022.

     

    Based on application, the market is fragmented into oncology, cardiology, immunology, respiratory diseases, and others. The oncology segment dominated the market in 2022. Based on end user, the market is segmented into hospitals, clinical laboratories, home care, and others. The clinical laboratories segment dominated the market in 2022.

     

    Based on country, the market is segmented into China, Japan, India, South Korea, Australia, and the rest of Asia Pacific. Further, China dominated the market in 2022.

     

    A few key players dominating the Asia Pacific precision diagnostics market are Abbott, Bayer AG, Koninklijke Philips N.V., Novartis AG, QIAGEN, Quest Diagnostics Incorporated, Sanofi, Siemens Healthineers AG, and Swiss Precision Diagnostics GmbH.

    The List of Companies - Asia Pacific Precision Diagnostics Market

    1. Abbott
    2. Bayer AG
    3. Koninklijke Philips N.V.
    4. Novartis AG
    5. QIAGEN
    6. Quest Diagnostics Incorporated
    7. Sanofi
    8. Siemens Healthineers AG
    9. Swiss Precision Diagnostics GmbH
    Frequently Asked Questions
    How big is the Asia Pacific Precision Diagnostics Market?

    The Asia Pacific Precision Diagnostics Market is valued at US$ 15,157.61 Million in 2022, it is projected to reach US$ 33,007.52 Million by 2028.

    What is the CAGR for Asia Pacific Precision Diagnostics Market by (2022 - 2028)?

    As per our report Asia Pacific Precision Diagnostics Market, the market size is valued at US$ 15,157.61 Million in 2022, projecting it to reach US$ 33,007.52 Million by 2028. This translates to a CAGR of approximately 13.8% during the forecast period.

    What segments are covered in this report?

    The Asia Pacific Precision Diagnostics Market report typically cover these key segments-

    • Type (Genetic Tests, Esoteric Tests)
    • Application (Oncology, Cardiology, Respiratory Diseases, Immunology)
    • End User (Clinical Laboratories, Hospitals, Homecare)

    What is the historic period, base year, and forecast period taken for Asia Pacific Precision Diagnostics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Precision Diagnostics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2028
  • Who are the major players in Asia Pacific Precision Diagnostics Market?

    The Asia Pacific Precision Diagnostics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Abbott
  • Bayer AG
  • Koninklijke Philips N.V.
  • Novartis AG
  • QIAGEN
  • Quest Diagnostics Incorporated
  • Sanofi
  • Siemens Healthineers AG
  • Swiss Precision Diagnostics GmbH
  • Who should buy this report?

    The Asia Pacific Precision Diagnostics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia Pacific Precision Diagnostics Market value chain can benefit from the information contained in a comprehensive market report.